Prelude Capital Management’s Cogent Biosciences COGT Stock Holding History

Prelude Capital Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.47M	Sell	64,222 -8,156	-11%	-$301K	0.19%	128
2025 Q4	$2.57M	Sell	72,378 -64,903	-47%	-$1.82M	0.19%	116
2025 Q3	$1.97M	Sell	137,281 -25,900	-16%	-$307K	0.15%	167
2025 Q2	$1.17M	Sell	163,181 -6,268	-4%	-$34.7K	0.11%	226
2025 Q1	$1.01M	Buy	+169,449	New	+$1.33M	0.08%	306
2023 Q4	–	Sell	-27,100	Closed	-$264K	–	1160
2023 Q3	$264K	Buy	+27,100	New	+$321K	0.02%	741
2023 Q2	–	Sell	-26,000	Closed	-$281K	–	1162
2023 Q1	$281K	Buy	+26,000	New	+$333K	0.02%	673

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Prelude Capital Management's COGT Position: Q1 2026 in Review

Prelude Capital Management reduced its Cogent Biosciences (COGT) stake by 11% in Q1 2026, selling an estimated $301K and leaving 64,222 shares worth $2.47M. The position accounts for 0.19% of the portfolio, ranked #128.

Prelude Capital Management first reported a position in COGT in Q1 2023 and has held it in 7 quarters since. The position peaked at $2.57M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

Prelude Capital Management held 64,222 shares of Cogent Biosciences worth $2.47M as of Q1 2026.
Prelude Capital Management sold 8,156 Cogent Biosciences shares in Q1 2026, an estimated $301K.
Cogent Biosciences made up 0.19% of Prelude Capital Management's portfolio in Q1 2026, its #128 holding.
Prelude Capital Management first reported a position in Cogent Biosciences in Q1 2023 and has held it in 7 quarters since.
Prelude Capital Management's Cogent Biosciences position peaked at $2.57M in Q4 2025.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.